Bavarian Nordic has been granted a patent for a vaccine combination that induces protective immunity against filovirus infections, including Ebola and Marburg viruses. The vaccine includes adenovirus and MVA vectors encoding specific antigenic proteins. GlobalData’s report on Bavarian Nordic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bavarian Nordic, Recombinant viral vaccines was a key innovation area identified from patents. Bavarian Nordic's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11918639B2) discloses a vaccine combination comprising two compositions. The first composition includes an adenovirus vector encoding an antigenic protein from a specific sequence, while the second composition contains an MVA vector encoding antigenic proteins from four filovirus subtypes. The patent claims specify the inclusion of adenovirus vectors encoding antigenic proteins from multiple filovirus subtypes, with specific sequences identified by SEQ ID numbers. The vaccine combination aims to generate a protective immune response against Ebola virus and can be used in the preparation of pharmaceutical compositions or medicaments.
Furthermore, the patent details the administration of adenovirus vectors, specifically rAd26 or rAd35 vectors, in a specified range of viral particles to human subjects. Similarly, the MVA vector is recommended to be administered within a defined range of TCID50 units. The patent's claims highlight the precise composition and administration guidelines for the vaccine combination, emphasizing its potential in eliciting a protective immune response against Ebola virus. The disclosed invention opens up possibilities for developing effective vaccines and pharmaceutical compositions to combat filovirus infections, particularly targeting the Ebola virus.
To know more about GlobalData’s detailed insights on Bavarian Nordic, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
